LEE'S PHARM (00950.HK): In-Licenses PARP1 Inhibitor OC-3 from 1cBio for Development and Commercialization in Greater China and Southeast Asia

NewTimeSpace News: On 9 September 2026, Lee's Pharmaceutical Holdings Limited (stock code: 00950) announced that its wholly owned subsidiary, Lee's Pharmaceutical (Hong Kong) Limited, has entered into an exclusive license agreement with US biotechnology company 1cBio, Inc. for the development, manufacture and commercialization of OC-3 in mainland China, Hong Kong, Macau, Taiwan and certain other Southeast Asian countries.

OC-3 is a next-generation selective PARP1 inhibitor currently in preclinical development, intended for the treatment of cancers with DNA homologous recombination repair deficiency, including prostate, ovarian, breast and pancreatic cancers with mutations in DNA repair genes such as BRCA1, BRCA2 or PALB2. Preclinical data show that OC-3 exhibits moderate PARP1 trapping activity, designed to potentially reduce hematological toxicity associated with non-selective PARP inhibitors while maintaining efficacy. Under the agreement, Lee's Pharmaceutical (Hong Kong) will be responsible for the GLP safety studies and manufacturing activities required for regulatory approvals of OC-3 in the territory, while 1cBio retains the right to access and use the data generated under the agreement for its planned Investigational New Drug application to the US FDA. 

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.